|Dr. Patrick W. Gray||CEO & Director||204.34k||N/A||1952|
|Ms. Judith F. Dalling L.L.B.||CFO & Corp. Sec.||65k||N/A||1955|
Pascal Biosciences Inc., a biopharmaceutical company, researches and develops products for the treatment of cancer, and for the enhancement of immune system. Its development portfolio includes PAS-403, a small molecule therapeutic advancing into clinical trials for the treatment of glioblastoma; and PAS-393, an immuno-stimulatory molecule to enhance the efficacy of checkpoint inhibitors. The company is also developing a B-cell targeted antibody for acute lymphoblastic leukemia and B cell lymphomas. The company has an exclusive license agreement with the University of Washington to develop a cannabinoid-based product for the treatment of glioblastoma multiforme and brain metastases; and a collaborative research agreement with SoRSE Technology Corporation to advance PAS-393 into clinical testing. Pascal Biosciences Inc. was founded in 2013 and is headquartered in Vancouver, Canada.
Pascal Biosciences Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.